QUINTAMED

Да

Development, marketing and sales of pharmaceutical products.

The company is 5 years old. 2 legal entities (Ukraine / Estonia).
The company is at the stage of scaling. Sales: 2nd year ~ 20,000 USD, 3rd year ~ 100,000 USD, 4th year ~ 300,000 USD.
The planned increase of the company's value from 2022 to 2030 is 7-14 times.
The planned amount of dividends is 11-25% per annum.

300000

42000

Tangible assets:
goods,
raw materials,
electronic and office devices.
Intangible assets:
trademarks,
technical documentation,
web-sites and social media

LLC

9

For each our product there is a market segment (capacity specified in the presentation).

The pharmaceutical market of Ukraine was 4 046 857 440 USD in 2019, 4 236 832 110 USD in 2020. And by results of the two quarters of 2021 shows growing dynamics (Q1+Q2 is 2 330 010 170 USD).

More information about the products - in the presentation.
The portfolio includes 14 products (12 in active promotion, 2 in development), which are used in the following therapeutic areas: cardiology, neurology, gastroenterology, paediatrics, dermatology, traumatology, gynaecology, urology, andrology, cosmetology, dentistry. Also on the market are 8 products of our partners (full potential of the portfolio - 52 positions).

The main competitors are the TOP-50 companies of the pharmaceutical market of Ukraine (TOP-20 in the dietary supplement segment).

Six of the twelve main products have unique differences and have no direct complete analogues at market.

The cost of products and sales forecasts - in the presentation.

At the moment our sales 350 000 USD per annum with only 2 regions, covering less than 7% of the total market. Our goal is to reach 3 000 000 USD sales in 2023 (1% of our market segment) and 9 000 000 USD in 2030 (3.2% of our market segment).

The first goal will be achievable when we will have representatives in each region (100% coverage of the market). And the second one we will achieve after portfolio expansion (+20 products). And the next step will be the export of products to other countries.

Sales channels - national pharmaceutical distributors, national and local pharmacy chains.
We currently have contracts with all major national pharmaceutical distributors, and our products are in the TOP-20 networks of Ukraine.

2 co-owners need cash-out

Markets and trands information - in presentation.

The volume of our current segment (our 12 active products) is 281 422 153 USD and will grow next 4 years (approx. +20% per year).

When we will expand our portfolio with 20 more products the market volume of our segment will be approx. 500 000 000 USD.